Key regions: Brazil, India, Australia, United States, United Kingdom
The market for antiviral drugs in Sweden has been growing steadily in recent years, driven by various factors such as rising prevalence of viral infections, increasing awareness about the benefits of antiviral drugs, and expanding healthcare infrastructure.
Customer preferences: Customers in Sweden are increasingly seeking antiviral drugs that offer a high degree of efficacy and safety, while also being affordable. They are also showing a growing preference for drugs that can be administered orally, rather than through injections or infusions. Additionally, there is a rising demand for antiviral drugs that can be used to treat multiple viral infections, rather than being limited to a specific type of virus.
Trends in the market: One of the key trends in the antiviral drugs market in Sweden is the growing use of combination therapies, which involve the use of multiple drugs to treat a single viral infection. This approach has been shown to be highly effective in combating viral infections, and is increasingly being adopted by healthcare providers in the country. Another trend is the development of newer, more advanced antiviral drugs that offer improved efficacy and safety profiles, as well as greater convenience and ease of use.
Local special circumstances: Sweden has a well-developed healthcare system, with a strong emphasis on preventive care and early intervention. This has helped to drive demand for antiviral drugs, as healthcare providers seek to prevent the spread of viral infections and reduce the severity of symptoms in infected individuals. Additionally, Sweden has a relatively high incidence of certain viral infections, such as hepatitis C, which has also contributed to the growth of the antiviral drugs market in the country.
Underlying macroeconomic factors: Sweden has a strong and stable economy, with a high level of per capita income and a well-educated workforce. This has helped to support the growth of the healthcare sector in the country, including the antiviral drugs market. Additionally, the government of Sweden has implemented a number of policies aimed at improving access to healthcare services, which has further boosted demand for antiviral drugs. Overall, the market for antiviral drugs in Sweden is expected to continue growing in the coming years, driven by a combination of demographic, economic, and healthcare-related factors.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
